Status: Recruiting

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).

Participants needed: 1,100

Trial details

Phase: Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: Vertex Pharmaceuticals IncorporatedUpdated: Jun 15, 2026Locations: 76

Eligibility criteria

Body weight greater than or equal to (≥) 45 kilogram (kg) [+3]

More than 3 missing daily NPRS scores during the 7-day Baseline Period [+1]

Status: Recruiting

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)

Participants needed: 300

Trial details

Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Vertex Pharmaceuticals IncorporatedUpdated: Jun 1, 2026Locations: 47

Eligibility criteria

Diagnosis of diabetes mellitus type 1 or type 2 with [+2]

Painful neuropathy other than DPN [+2]

Status: Recruiting

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine in participants with pain associated with diabetic peripheral neuropathy (DPN).

Participants needed: 734

Trial details

Phase: Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: Vertex Pharmaceuticals IncorporatedUpdated: May 19, 2026Locations: 75

Eligibility criteria

Body weight greater than or equal to (≥)45 kilogram (kg) [+3]

More than 3 missing daily NPRS scores during the 7-day Baseline Period [+2]

Status: Recruiting

A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain

This study aims to investigate the efficacy and safety of HRS-2129 in Chinese diabetic peripheral neuropathic pain (DPNP) in comparison to placebo.

Participants needed: 168

Trial details

Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Shandong Suncadia Medicine Co., Ltd.Updated: Apr 15, 2026Locations: 2

Eligibility criteria

Able and willing to provide a written informed consent. [+4]

Subjects with a history of severe allergies. [+6]

Status: Recruiting

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain

The purpose of this study is to test the safety and efficacy of study drug LY4065967 for the treatment of diabetic peripheral neuropathic pain (DPNP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.

Participants needed: 150

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Eli Lilly and CompanyUpdated: Mar 27, 2026Locations: 37

Eligibility criteria

Have presence of diabetic peripheral neuropathy, of symmetrical nature and in lo... [+3]

Are pregnant or breastfeeding [+5]

Status: Not yet recruiting

Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain

This is a multi-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and PK parameter of HL-1186 tablet for diabetic peripheral neuropathic pain.

Participants needed: 180

Trial details

Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Updated: Sep 8, 2025

Eligibility criteria

Aged between 18 and 75 years old (inclusive), regardless of gender. [+4]

Participants with any pain other than DPNP, or with other diseases that the inve... [+14]

Status: Recruiting

MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP

This Phase I, randomized, double-blind and placebo controlled study is to evaluate the safety, tolerability, and PK, and to preliminarily assess the efficacy of topically administered YJ001 in a multiple-ascending dose (MAD) fashion in the patients with DPNP. The study will be conducted at a single study center. In this study, 2 cohorts (N=24, 12 subjects for each cohort), each cohort will consist of 10 active and 2 placebo, with approximately equal numbers of male and female subjects. Each subject will be administered a single dose of YJ001 as multiple sprays topically on both feet and below the ankle in the morning on Day 1 and Day 2, and will be administered as twice daily doses once in the morning and the other in the evening (with an interval of 11 to 13 h) from Day 3 through Day 11.

Participants needed: 24

Trial details

Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.Updated: Aug 13, 2025Locations: 1

Eligibility criteria

Male or female, between the ages of 18 to 80 years at screening, both inclusive. [+13]

Current participation in another investigational drug or device study or treated... [+29]

Status: Recruiting

Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to Pregabalin

Investigate the efficacy and safety of HSK16149 capsule in Chinese patients with Diabetic Peripheral Neuropathic Pain (DPNP) who had an inadequate response to Pregabalin, following 4 weeks treatment in comparison to Pregabalin

Participants needed: 90

Trial details

Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Haisco Pharmaceutical Group Co., Ltd.Updated: Jul 8, 2024Locations: 1

Eligibility criteria

Signed informed consent; [+5]

Peripheral neuropathy or pain unrelated to DPN that may confuse the assessment o... [+17]